The XEC COVID-19 variant, first identified in Europe, now accounts for 45 percent of cases in the United States, according to the Centers for Disease Control and Prevention (CDC). As infections tick ...

Historically, COVID-19 symptoms have been fevers or chills, cough, shortness of breath, cough, congestion or a runny nose, ...

Invivyd Inc. (NASDAQ:IVVD) announced that new in vitro neutralization data show continued neutralizing activity of Pemgarda ...

Covid symptoms have largely stayed the same over the last few years: cough, congestion, fever, a sore throat, nausea, ...

THE historic massive landslide victory of Donald J. Trump in all sectors of the American electorate last November gave the 47th president of the United States a clear resounding ...

Although the worst of COVID-19 may be behind us, Springfield’s Health and Human Services Commissioner Helen Caulton-Harris ...

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC Centers for Disease ...

Invivyd (IVVD) announced that new in vitro neutralization data show continued neutralizing activity of PEMGARDA and pipeline candidate VYD2311 ...

Highlights,PEMGARDA™ shows sustained neutralizing activity against the XEC variant, covering 69% of U.S. variants.,The drug has demonstrated effectiveness against over 75% of circulating U.S. variants ...

and pipeline candidate VYD2311 against dominant SARS-CoV-2 variant XEC. As anticipated based on the structural biology of pemivibart and VYD2311, the data are largely consistent with those ...